340B Tops $100 Billion as Congress Moves to Reform

The 340B program has reached a symbolic and political turning point. According to HRSA data reported in July, discounted purchases under the program hit at least $100 billion in 2025 — a milestone that industry analysts say raises a hard question: has 340B become too big to reform? Congress apparently doesn’t think so. Within two weeks of that report, lawmakers in both chambers put serious reform vehicles on the table.

Two Reform Efforts, One Common Thread

On June 25, Senate HELP Committee Chairman Bill Cassidy (R-LA) released a long-anticipated discussion draft that would reshape core mechanics of the program — including manufacturer rebate structures, contract pharmacy limits, and new transparency requirements for how covered entities use their savings. Days later, Representatives Scott Peters (D-CA) and Dave Joyce (R-OH) unveiled a bipartisan House bill aimed at improving the discount drug pricing program, signaling that reform interest is not confined to one party or one chamber.

The common thread across both efforts is accountability: policymakers want covered entities to demonstrate that 340B savings reach patients. Separately, the House has advanced new reporting requirements for tax-exempt hospitals, adding another layer of scrutiny to how safety-net providers document community benefit.

Why This Matters For Ryan White Clinics and STD Programs

Smaller covered entities: Ryan White clinics, hemophilia treatment centers, STD clinics — were not the target of the $100 billion headline, but they will live under whatever rules emerge. Entities that can clearly show a direct line from 340B savings to patient benefit will be best positioned, whether the final framework includes reporting mandates, rebate models, or transparency scoring.

PIAP: One of the Clearest Patient-Benefit Story in 340B

A Premium Insurance Assistance Program (PIAP) uses 340B savings to pay insurance premiums and cost-sharing for uninsured and underinsured patients. That produces exactly the evidence reformers are asking for:

• A documented, auditable use of savings tied to named patients and paid premiums — not a general fund.
• Patients gain comprehensive commercial coverage, including primary care, behavioral health, and specialty services beyond HIV care.
• The clinic generates commercial reimbursement revenue, reducing dependence on grants while strengthening the program’s community-benefit case.

In a reform environment focused on where the money goes, a PIAP converts your 340B program from a question mark into a proof point.

What to Do Now? 

Don’t wait for final legislative language. Map how your entity currently uses 340B savings, identify the share that directly funds patient services, and evaluate whether a structured premium assistance program would strengthen both your finances and your compliance narrative. American Exchange has helped covered entities across the country stand up PIAPs that are audit-ready from day one.

Ready to make your 340B savings tell a clear patient-benefit story? Schedule time to meet with our team to discuss.